EYPT
Eyepoint Pharmaceuticals Inc
3.60$
-0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -48.6% | +135.4% | +0.8% | +64.6% | +72.3% | +94.7% | +249.9% | +89.5% | -78.5% | -29.0% | -39.2% | +62.1% | +664.9% | +0.0% | -93.9% | +365.4% | -22.3% | +247.8% | +69.1% | +7.3% | +12.1% | +11.1% | -6.0% | -27.5% | |
| – | – | – | – | – | -46.1% | +118.8% | -44.6% | -75.1% | +0.9% | +109.8% | -0.5% | +36.7% | +26.3% | +19.0% | +3.5% | +8.7% | +14.4% | -85.5% | +116.7% | +40.4% | +1.8% | -44.4% | -19.9% | -44.3% | |
| – | -48.6% | +137.4% | +0.0% | +132.8% | -729.8% | – | +249.9% | +62.2% | -91.8% | +119.0% | -237.9% | – | – | +83.5% | -93.9% | +365.4% | -284.8% | – | +61.9% | +0.5% | +15.0% | +25.1% | -4.4% | -25.9% | |
| – | +71.6% | +58.1% | +29.2% | +0.0% | +85.9% | +71.2% | -28.0% | -44.5% | -12.7% | +0.6% | +0.0% | +36.0% | +0.0% | +26.3% | +19.0% | +3.5% | +39.9% | -26.2% | +13.4% | +63.6% | +74.2% | +30.3% | +105.6% | +66.3% | |
| – | – | +77.8% | +56.4% | – | – | – | +0.0% | -37.0% | -20.7% | -1.4% | +4.4% | +4.2% | +0.0% | +7.9% | +11.9% | +24.7% | +37.1% | +16.5% | +15.5% | +23.4% | +36.1% | +15.2% | +30.6% | -1.4% | |
| – | +1,159.2% | +133.4% | -28.3% | +167.8% | -27.1% | +33.5% | -40.8% | -36.7% | +9.2% | +85.4% | -66.7% | +3.1% | +9.0% | +150.0% | +16.1% | +11.6% | +100.4% | +25.3% | +0.6% | +27.5% | +57.9% | -12.3% | +59.2% | +47.1% | |
| – | – | – | – | – | – | – | – | – | -210.0% | – | – | – | – | +0.0% | -439.1% | – | – | – | – | – | – | – | – | – | |
| – | – | +0.0% | -100.0% | – | +181.3% | -94.7% | +0.0% | -100.0% | – | -92.3% | -100.0% | – | -50.0% | -100.0% | – | – | +0.0% | +757.8% | +17.5% | -24.2% | -42.0% | -60.9% | -98.9% | +135.7% | |
| – | – | – | – | – | – | – | – | – | -200.8% | – | – | – | – | +0.0% | -436.8% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -1,047.8% | – | -169.2% | – | -26.2% | +0.0% | -261.5% | – | – | – | +17.5% | -24.2% | +304.8% | -99.6% | +8.4% | +210.0% | |
| – | – | – | – | – | – | – | – | – | -198.6% | – | – | – | – | +0.0% | -439.5% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -153.5% | – | – | – | – | +0.0% | -385.7% | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.